These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37019903)

  • 1. Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation.
    Papadopoulos N; Nédélec A; Derenne A; Şulea TA; Pecquet C; Chachoua I; Vertenoeil G; Tilmant T; Petrescu AJ; Mazzucchelli G; Iorga BI; Vertommen D; Constantinescu SN
    Nat Commun; 2023 Apr; 14(1):1881. PubMed ID: 37019903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
    Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
    Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
    Pecquet C; Papadopoulos N; Balligand T; Chachoua I; Tisserand A; Vertenoeil G; Nédélec A; Vertommen D; Roy A; Marty C; Nivarthi H; Defour JP; El-Khoury M; Hug E; Majoros A; Xu E; Zagrijtschuk O; Fertig TE; Marta DS; Gisslinger H; Gisslinger B; Schalling M; Casetti I; Rumi E; Pietra D; Cavalloni C; Arcaini L; Cazzola M; Komatsu N; Kihara Y; Sunami Y; Edahiro Y; Araki M; Lesyk R; Buxhofer-Ausch V; Heibl S; Pasquier F; Havelange V; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
    Blood; 2023 Feb; 141(8):917-929. PubMed ID: 36356299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.
    Pecquet C; Chachoua I; Roy A; Balligand T; Vertenoeil G; Leroy E; Albu RI; Defour JP; Nivarthi H; Hug E; Xu E; Ould-Amer Y; Mouton C; Colau D; Vertommen D; Shwe MM; Marty C; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
    Blood; 2019 Jun; 133(25):2669-2681. PubMed ID: 30902807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
    Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
    Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
    Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
    Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.
    Tvorogov D; Thompson-Peach CAL; Foßelteder J; Dottore M; Stomski F; Onnesha SA; Lim K; Moretti PAB; Pitson SM; Ross DM; Reinisch A; Thomas D; Lopez AF
    EMBO Rep; 2022 Apr; 23(4):e52904. PubMed ID: 35156745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
    Araki M; Yang Y; Imai M; Mizukami Y; Kihara Y; Sunami Y; Masubuchi N; Edahiro Y; Hironaka Y; Osaga S; Ohsaka A; Komatsu N
    Leukemia; 2019 Jan; 33(1):122-131. PubMed ID: 29946189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
    Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
    Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
    Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
    J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
    Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
    Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
    Araki M
    Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven activation from cytokine-induced stimulation.
    Papadopoulos N; Pristavec A; Nédélec A; Levy G; Staerk J; Constantinescu SN
    Blood; 2023 Nov; 142(21):1818-1830. PubMed ID: 37616564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
    Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
    Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
    Jia R; Balligand T; Atamanyuk V; Nivarthi H; Xu E; Kutzner L; Weinzierl J; Nedelec A; Kubicek S; Lesyk R; Zagrijtschuk O; Constantinescu SN; Kralovics R
    Blood; 2021 Apr; 137(14):1920-1931. PubMed ID: 33202418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
    Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
    Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of calreticulin mutations in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In and out: Traffic and dynamics of thrombopoietin receptor.
    Roy A; Shrivastva S; Naseer S
    J Cell Mol Med; 2021 Oct; 25(19):9073-9083. PubMed ID: 34448528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.